July 28, 2016 1:28 AM ET

Pharmaceuticals

Company Overview of Marinus Pharmaceuticals, Inc.

Company Overview

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. It is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of orphan disease, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing an IV formulation for use in the hospital setting to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agr...

3 Radnor Corporate Center

100 Matsonford Road

Suite 304

Radnor, PA 19087

United States

Founded in 2003

12 Employees

Phone:

484-801-4670

Key Executives for Marinus Pharmaceuticals, Inc.

Executive Chairman, Chief Executive Officer and President
Age: 59
Total Annual Compensation: $651.8K
Chief Financial Officer, Vice President, Treasurer and Secretary
Age: 45
Total Annual Compensation: $457.7K
Chief Medical Officer
Age: 51
Total Annual Compensation: $434.5K
Compensation as of Fiscal Year 2015.

Marinus Pharmaceuticals, Inc. Key Developments

Marinus Pharmaceuticals, Inc. Announces Top-Line Data from Phase 2 Exploratory

Marinus Pharmaceuticals, Inc. announced top-line data from a Phase 2 exploratory, investigator-sponsored study to evaluate the safety, tolerability and efficacy of ganaxolone for the treatment of anxiety and attention in children with Fragile X Syndrome (FXS). The investigator selected Clinical Global Impression of Improvement (CGI-I), which is a broad scale to assess the overall improvement across the entire Fragile X Syndrome, as the primary endpoint of the study. While this primary endpoint was not met, consistent with Marinus’ expectations and ganaxolone’s mechanism of action, treatment with ganaxolone improved anxiety and hyperactivity across multiple measures in FXS patients with high baseline anxiety. The results from this study support the anxiolytic effect of ganaxolone and provide a strong rationale for Marinus to advance the clinical development of ganaxolone in anxious FXS patients. The Phase 2 study enrolled 59 children between 6 and 17 years of age with a diverse range and severity of FXS-related symptoms. The trial utilized multiple clinician- and parent-administered rating scales designed to identify a signal among a variety of symptoms common to FXS children. Twenty-nine of the treated patients had a high level of anxiety at baseline (defined as baseline Pediatric Anxiety Rating Scale (PARS) =13) and showed improvements in anxiety, attention and hyperactivity as measured by scales designed to detect these symptomatic changes (Visual Analog Scale (VAS), Anxiety, Depression & Mood Scale (ADAMS), and Aberrant Behavior Checklist (ABC)).

Marinus Pharmaceuticals, Inc. - Special Call

To report the results from the Phase 2 investigator-sponsored, exploratory study evaluating ganaxolone in children with Fragile X Syndrome

Marinus Pharmaceuticals, Inc. Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV

Marinus Pharmaceuticals, Inc. announced that it has dosed the first subject in its Phase 1 clinical trial of ganaxolone IV, an intravenous (IV) formulation of Marinus CNS-selective GABAA modulator, for the treatment of status epilepticus (SE). The study is designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ganaxolone IV in healthy volunteers, with data anticipated in the second half of 2016. The Phase 1 study, which will be conducted at Duke University Medical Center, will include a dose escalation of a bolus dosage of ganaxolone IV and a bolus dose of ganaxolone IV, followed by a continuous infusion. The primary study objective is to evaluate the safety and PK of ganaxolone IV. The secondary study objectives include the PD effects of ganaxolone IV on electroencephalogram (EEG) parameters and ventilation, as well as the effect of ganaxolone IV on clinical sedation scores.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Marinus Pharmaceuticals, Inc., please visit www.marinuspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.